Prediction tool could make CRISPR-Cas9 editing more reliable

Online tool can help researchers correct pathogenic mutations and restore genes to healthy state

ERS Genomics Limited and DefiniGEN Ltd announced a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents

Enzyme can target almost half of the genome's "zipcodes" and could enable editing of many more disease-specific mutations

A disorder known as "autosomal recessive" occurs in a child if they inherit one mutated gene from the mother and one from the father

Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation

Why do individuals carrying identical gene mutations for a disease end up having varying severity or symptoms of the disease?

New study sheds light on biology of most-used Cas9 target

An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation

New platform transforms gene editor into precision tool